electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
electroCore (NASDAQ: ECOR) has completed its merger with NeuroMetrix (NASDAQ: NURO), acquiring the Quell® Fibromyalgia Solution platform. The acquisition positions electroCore as a leading player in non-invasive bioelectronic technologies, expanding its portfolio in chronic pain and wellness markets. Under the merger terms, NURO shareholders received $4.49 per share in cash plus one contingent value right (CVR) tied to future Quell business sales milestones and proceeds from DPNCheck business disposition.
The strategic acquisition is expected to leverage electroCore's established distribution channels, particularly within the VA Hospital System, to accelerate Quell Fibromyalgia solution adoption. Following the merger completion, NeuroMetrix became an indirect wholly-owned subsidiary of electroCore, with NURO shares being delisted from Nasdaq on May 2, 2025.
electroCore (NASDAQ: ECOR) has announced that its wellness product Truvaga Plus, a hand-held vagus nerve stimulator, is now compatible with the Apple Health app. The integration allows users to track their mental wellbeing data alongside other health metrics in one consolidated platform.
Through the State of Mind API, users can log and monitor their emotional state after each Truvaga Plus session within the Health app's Mental Wellbeing category. Truvaga Plus is designed to provide stress relief, improve sleep, enhance peace of mind, and boost focus through gentle vagus nerve activation.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025, after market close.
The company will host a webinar at 4:30 PM EST where management will review financial results and conduct a Q&A session. Investors interested in participating can access the webinar through:
- Dial-In Number: (646) 931-3860
- Webinar ID: 885 4355 1292
- Passcode: 419231
A registration link is provided for those who wish to participate and ask questions during the call.
electroCore (Nasdaq: ECOR) announced new data demonstrating the effectiveness of gammaCore non-invasive vagus nerve stimulation (nVNS) in treating concussion symptoms from mild traumatic brain injury (mTBI). The study, presented at the 2025 International Brain Injury Association World Congress, involved 102 patients and showed significant improvements in 22 out of 27 measured concussive symptoms.
Key findings revealed notable improvements in post-traumatic headache, nausea, dizziness, and depression. Importantly, the treatment showed similar effectiveness regardless of injury timing, benefiting both recent cases (under three months) and older injuries (over three years), suggesting neuromodulation's potential as a long-term treatment option.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has announced its participation in the upcoming Planet MicroCap Showcase at the Paris Hotel & Casino in Las Vegas on April 23 & 24, 2025.
CEO Dan Goldberger will deliver a group presentation on Wednesday, April 23, 2025, at 1:30 p.m. PT and will be available for one-on-one meetings throughout the event. Interested investors can schedule meetings through Planet MicroCap or by contacting electroCore's investor relations at ecor@fnkir.com.
electroCore (Nasdaq: ECOR), a bioelectronic medicine and wellness company, has achieved significant recognition by ranking #125 on the Financial Times' 'The Americas' Fastest Growing Companies 2025' list. The company secured this position based on its compound annual revenue growth between 2020 and 2023.
In the healthcare & life sciences sector, which represented 10% of the fastest-growing companies, electroCore ranked 16th among 30 healthcare companies, alongside notable peers like BeiGene, Hims & Hers Health, and Progyny. The company specializes in providing drug-free solutions for pain management, stress reduction, and sleep improvement.
The prestigious Financial Times ranking, now in its sixth year, was announced on April 2, 2025, featuring 300 top-performing companies across various sectors in the Americas.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has announced its participation in the upcoming Needham Virtual Healthcare Conference on April 10, 2025.
CEO Dan Goldberger and CFO Joshua Lev will deliver a group presentation at 2:15 p.m. ET and engage in one-on-one meetings throughout the conference day. The presentation will be accessible via live audio webcast, with a replay option available.
Investors interested in meeting with management during the conference can arrange meetings through their Needham representative or by contacting FNK IR at ecor@fnkir.com.
electroCore (ECOR) has secured a new five-year Federal Supply Schedule (FSS) contract with the Veterans Affairs (VA), effective from June 15, 2025, through June 14, 2030. The renewal comes after the VA's termination of 585 non-mission critical contracts, highlighting gammaCore's strategic importance.
The company reported accelerated revenue from VA hospitals in February and March 2025, following a slight slowdown in January, indicating sustained demand for their drug-free migraine treatment solution. The new contract includes provisions for prompt pay discounts and volume rebates for revenues exceeding $10 million per calendar year.
electroCore (ECOR) reported record financial results for full year 2024, achieving net sales of $25.2 million, a 57% increase from $16.0 million in 2023. The growth was primarily driven by an 85% increase in Rx gammaCore sales through VA/DOD channels and a 174% rise in Truvaga sales.
The company's net loss decreased by 37% to $11.9 million in 2024, with gross profit reaching $21.4 million at an 85% margin. Operating expenses totaled $33.6 million, including $2.4 million in R&D and $31.2 million in SG&A costs. Cash burn improved significantly, with net cash used in operations decreasing 53% to $7.0 million.
The company ended 2024 with $12.2 million in cash and equivalents, up from $10.6 million at the end of 2023. The adjusted EBITDA net loss improved to $9.0 million from $15.4 million in the previous year.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has scheduled its fourth quarter and full year 2024 financial results announcement for Wednesday, March 12, 2025, after market close. The company will host a webcast and conference call at 5:30 PM EDT where management will discuss the financial results and conduct a Q&A session.